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Abstract
Transcatheter aortic valve replacement (TAVR) has been established as a therapeutic option for patients with severe symptomatic aortic
stenosis who are of intermediate or higher surgical risk. Several periprocedural complications are reduced with newer transcatheter heart
valve generations; however, conduction abnormalities and the need for permanent pacemaker implantation have remained unchanged and
are the most frequent TAVR complications. The close relationship of the atrioventricular node and left bundle branch to the subaortic region
explains these potential conduction abnormalities. This article highlights conduction abnormalities after TAVR with a focus on basic conduction
system anatomy in relation to the aortic valve, the mechanism, incidence, predisposing factors for occurrence, impact on mortality and finally,
proposed treatment algorithms for management.
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Transcatheter aortic valve replacement (TAVR) has been established
as a therapeutic option for patients with severe symptomatic aortic
stenosis who are considered to be of intermediate, high or prohibitive
surgical risk.1–5 As a result of favorable TAVR outcomes and substantial
improvements in transcatheter heart valve (THV) technologies and
implantation techniques, the feasibility of broadening applications to
the low-risk population is being evaluated.
Despite periprocedural complications being reduced with newer THV
generations, the occurrence of conduction abnormalities and the
need for permanent pacemaker implantation (PPI) remain the most
frequent complications. 6,7 Rates of PPI have not been significantly
reduced but rather, with some technologies, have increased.8 The
long-term implications of PPI in the TAVR patient population remain
unclear, and applicability in low-risk patients is a further consideration.
In addition, short-term implications may jeopardize the minimalist
TAVR approach, with increased use of electrophysiological studies
and continuous EKG monitoring devices (i.e. Holter monitors, event
monitors, or implantable loop recorders), and subsequent prolonged
length of hospital stay.9–12
This article highlights conduction abnormalities after TAVR with a focus
on basic conduction system anatomy in relation to the aortic valve, the
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mechanism, incidence, predisposing factors for occurrence, impact on
mortality, and finally, proposed treatment algorithms for management.

Anatomy of the Conduction System
The atrioventricular node (AVN) is located within the triangle of Koch,
which is demarcated by the tendon of Todaro, the septal leaflet
attachment of the tricuspid valve, and the orifice of the coronary sinus
(Figure 1). The AVN continues as the His bundle, tracking through the
septum leftward to the central fibrous body. The central fibrous body
is the area within the heart where the membranous septum (MS), the
atrioventricular valves, and the aortic valve join in continuity. The left
bundle branch exits within this area between the non-coronary cusp
(NCC) and right coronary cusp (RCC) leaflets and travels along the septal
surface of the left ventricular septum.13,14 The close relationship of the
AVN and left bundle branch to the subaortic region explains the potential
conduction abnormalities after percutaneous THV insertion.

Conduction Abnormalities after Surgical
Aortic Valve Replacement
The most common conduction abnormality after surgical aortic valve
replacement (SAVR) is left bundle branch block (LBBB). The incidence of
new LBBB after SAVR has been reported to range from 6% to 32%.15–17
It is caused by injury to the conduction system at the interleaflet
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Figure 1: Schematic Illustration of Intracardiac Anatomy and
Relationship to Atrioventricular Node
Tendon of Todaro
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triangle of the NCC/RCC leaflets from direct surgical trauma during
decalcification, mechanical compression, hemorrhage, or ischemia.15–17
New LBBB after SAVR was found to be associated with worse 1-year
survival, when compared with cases where LBBB did not develop.15,18
SAVR can be performed by using either stented or stentless biological
prostheses. Stented biological prostheses can be implanted in a supraannular or intra-annular position; the valve does not generate a
radial force that compresses the conduction system if implanted in
a supra-annular position. Stentless valve prostheses are designed to
achieve a more physiological flow pattern and superior hemodynamics in
comparison with stented valves.19 Some generations of stentless valves
require only one suture line to secure the valve.19
Recent technological developments have led to an alternative, minimallyinvasive option that avoids the placement of sutures, known as sutureless
or rapid-deployment aortic valves (Su-AVR). Su-AVR, which combines
features of both SAVR and TAVR, requires removal/decalcification of native
leaflets, but depends on its intra-annular stent design with oversizing to
anchor the prosthesis.20 Conduction abnormalities associated with this
valve type are more similar to with TAVR than SAVR.21

Conduction Abnormalities After Transcatheter
Aortic Valve Replacement
TAVR prostheses are placed in an intra-annular position in closer
proximity to the AVN and left bundle branch. In contrast to surgical
valves, they are anchored into the aortic annulus and their stent frames
generate a radial force expansion that may compress the conduction
system.21 Slight oversizing is necessary in implant technique to secure the
THV and reduce paravalvular regurgitation; however, excessive oversizing
can result in increased compression of the conduction system.22 Overall,
TAVR patients have a higher incidence of conduction abnormalities than
patients who have conventional SAVR.21

Incidence of New-onset Left Bundle Branch Block
and Permanent Pacemaker Insertion
New-onset LBBB is the most frequent complication after TAVR.6 The
incidence of new-onset LBBB ranges from 4% to 57%, with the rate of
PPI ranging from 2% to 51%.23,24 The incidence of both new-onset LBBB
and PPI are higher after implantation with the self-expanding CoreValve®
system (MCV, Medtronic) than with the balloon-expandable SAPIEN
or SAPIEN XT systems (ESV, Edwards Lifesciences); new-onset LBBB
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and PPI are 35–65% and 28%, and 3–30% and 6%, for MCV and ESV,
respectively.25–34 Table 1 summarizes studies with their associated LBBB
and PPI rates. The higher incidence of PPI in the MCV compared with the
ESV has been confirmed in a randomized controlled trial.35
Overall, LBBB leads to an increased likelihood of new PPI early after
TAVR.36 However, one-fifth to nearly half of new-onset LBBB is temporary.37
Testa et al. studied 1,060 patients treated with MCV; 43.0% developed
LBBB after TAVR, and this figure decreased to 27.3% at discharge and
remained stable at 30 days.25 Urena et al. reported the rate of new-onset
LBBB to be approximately 20.0% after TAVR with ESV and that 50.0% of
new-onset LBBB resolved within a few days after TAVR, leading to a rate
of new-onset persistent LBBB of approximately 10.0%.38 In another study,
Franzoni et al. showed a higher incidence of LBBB following MCV (50.0%)
than ESV (13.5%), which reduced by discharge to 32.2% for MCV and 8.6%
for ESV, respectively.39
LBBB is also a predictor of late PPI after hospital discharge.40,41 In a
recent meta-analysis, a higher rate of PPI at 1-year follow up was
observed among patients with new-onset LBBB, compared with those
who did not develop LBBB.41 The frequency of LBBB after TAVR has
decreased significantly over time, especially with MCV THVs. This has
been largely attributed to operator experience and the subsequent
reduction in implantation depth.42 Nevertheless, the incidence of PPI
has remained unchanged over time and has not been affected by
operator experience.42 When interrogation of permanent pacemakers
are performed, approximately 50% of patients are continuously paced,
25% are intermittently paced, and 25% have adequate atrioventricular
conduction without the necessity of pacing.37 The patient population with
persistent LBBB who require PPI and have identifiable need upon followup interrogation still require improved understanding.

Newest Third-generation Transcatheter Heart Valves
Increased rates of PPI, ranging from 12.4% to 25.5%, have been
reported with the use of the newest third-generation ESV SAPIEN 3,
when compared with previous generations.43–49 This finding has been
attributed to the incorporation of an external fabric cuff in the inferior
part of the valve, intended to minimize paravalvular leak. Moreover,
different stent expansion patterns of the SAPIEN 3 compared with the
SAPIEN XT may play a role.50 In SAPIEN XT, the expansion area increased
from the inflow level, reaching its peak at the outflow level; in contrast,
the SAPIEN 3 has its largest expansion at the left ventricular outflow
tract (LVOT) end, causing elevated localized pressure within the LVOT
and thus higher rates of atrioventricular conduction disturbances.50 A
higher (>70% aortic extension) valve depth implantation of this newestgeneration THV may decrease PPI risk.43,44 Also, the next-generation selfexpanding MCV Evolut Pro has been designed with an external pericardial
wrap with the intention of reducing paravalvular leak. Early PPI rates in the
first 60 patients were reported at 30 days at 11.7%.51 Although 6-month
data suggest no significant change in PPI, data for this THV are limited.

Impact of Transcatheter Aortic Valve Replacementinduced Left Bundle Branch Block on Mortality
LBBB has been associated with increased morbidity and mortality in
a broad population of patients, from healthy individuals to patients
who have had MI and have established heart failure.52,53 However,
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Table 1: Summary of Studies Showing the Incidence of LBBB and PPI Following TAVR
and Respective Association with Mortality
Author

Patients

Valve

Incidence of

Incidence of

(n)

Type

LBBB (%)

PPI (%)

Risk Factors for LBBB/PPI

Association of TAVRinduced LBBB/PPI and
Mortality

Chamandi et al. 2018

90

1,629

45% ESV
55% MCV

N/A

19.8% at 30 days N/A
post-TAVR
(26.9% of MCV,
10.9% of ESV)

PPI was associated with an
increased risk of heart failure
rehospitalization and lack of
LVEF improvement, but not
mortality

Fadahunsi et al. 201676
(STS/ACC TVT registry)

9,785

ESV
MCV

N/A

6.7% at 30
PPI: age, prior conduction defect, use of
days post-TAVR self-expanding valve, large prosthesis, valve
(25.0% of MCV
oversizing
and 4.3% of ESV)

PPI was associated with
increased mortality and a
composite of mortality or heart
failure admission at 1 year

Mauri et al. 201667

229

ESV3

N/A

14.4%

PPI: deep THV implantation, higher LVOT
calcium in the area below LCC and RCC, preexisting RBBB

N/A

Van der Boon et al.
201542

549

ESV
MCV

New-onset LBBB
33.7%

13.3%
(7.6% of
TAVR-induced
LBBB patients
underwent PPI)

LBBB: Use of MCV, transfemoral approach,
deep THV implantation

N/A

Nazif et al. 201573
(PARTNER trial
and registry)

1,973

ESV

N/A

8.8%

PPI: RBBB, prosthesis/LVOT diameter, LVEDD

PPI was associated with
higher repeat hospitalization
and mortality or repeat
hospitalization at 1 year

Urena et al. 201438

668

ESV

New-onset LBBB
19.2%
Persistent LBBB
11.8%

N/A
Higher rate of
PPI in LBBB
group

LBBB: Transapical approach, a
29-mm valve

LBBB did not increase the risk
of global or cardiovascular
mortality or rehospitalization
at 1 year

Nazif at al. 201458
(PARTNER trial
and registry)

1,307

ESV

New-onset LBBB
10.5%

N/A
Higher rate of
PPI in LBBB
group

LBBB: Prior CABG

LBBB was not associated with
1-year mortality, cardiovascular
mortality, repeat hospitalization,
stroke, or MI

Testa at al. 201325

818

MCV

Persistent LBBB
27.4%

N/A
PPI: Deep THV implantation
Higher rate of
(>8 mm)
PPI at 30 days in
persistent LBBB
group

LBBB was not associated with
increased all-cause mortality,
cardiac mortality, hospitalization
for heart failure at 30 days or
1 year.

Franzoni at al.201339

238

63.4% ESV New-onset LBBB
36.6%
26.5% (13.5%
MCV
ESV, 50.0% MCV)
Persistent LBBB:
8.6% ESV, 32.2%
MCV

12.7%

LBBB: Use of MCV

LBBB was not associated
with overall or cardiovascular
mortality

57% MCV
43% ESV

New-onset LBBB
34.3%

N/A

N/A

LBBB increased all-cause
mortality
LBBB was not associated with
mortality at 1 year

Houthuizen et al. 201226 679
Urena et al. 201233

202

ESV

New-onset LBBB
30.2%

N/A

LBBB: Baseline QRS, deep THV implantation

De Carlo et al. 201227

275

MCV

New-onset LBBB
26.9%

24%

PPI: Deep THV implantation, RBBB, left anterior PPI did not affect 1-year
hemiblock, longer PR interval
survival

Aktug et al. 201228

139

ESV
MCV

New-onset LBBB
29.0%
(38.0% in MCV,
16.0% in ESV)
Persistent LBBB
12.9%

17.2%
(28.0% MCV,
5.0% ESV)

LBBB: Deep THV implantation, use of MCV
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Table 1: Continuted
Author

Patients

Valve

Incidence of

Incidence of

(n)

Type

LBBB (%)

PPI (%)

Risk Factors for LBBB/PPI

Association of TAVRinduced LBBB/PPI and
Mortality

Laynez et al. 2012

125

ESV

New-onset LBBB
4%

4%

N/A

N/A

Khawaja et al. 201131

243

MCV

New-onset LBBB
61%

33.3%

PPI: Periprocedural AVB, balloon
predilatation, CoreValve prosthesis, increased
interventricular septum diameter, prolonged
QRS

N/A

Baan et al. 201077

34

MCV

New-onset LBBB
65%

20.5% (7/34
patients)

LBBB: Deep THV implantation
PPI: Pre-existing conduction abnormalities,
narrow LVOT, postprocedural small EOA, more
mitral annular calcification

N/A

Piazza et al. 201032

91

MCV

New-onset LBBB
54%

19%

LBBB: Male sex, pre-existing RBBB, depth of
N/A
implantation, actual diameter of inflow portion
of CoreValve frame
PPI: Baseline QRS, septal wall thickness

34

AVB = atrioventricular block; CABG = coronary artery bypass graft; EOA = effective orifice area; ESV = Edwards SAPIEN valve; LBBB = left bundle branch block; LCC = left coronary cusp; LVEDD = left
ventricular end-diastolic dimension; LVEF = left ventricular ejection fraction; LVOT = left ventricular outflow tract; MCV = Medtroic CoreValve; PARTNER = Placement of AoRtic TraNscathetER Valves;
PPI = permanent pacemaker implantation; RBBB = right bundle branch block; RCC = right coronary cusp; STS/ACC TVT = Society of Thoracic Surgeons/American College of Cardiology Transcatheter
Valve Therapy; TAVR = transcatheter aortic valve replacement; THV = transcatheter heart valve.

there are conflicting data about the impact of new-onset LBBB on
mortality in post-TAVR patients. Several studies have failed to show
the relationship between new-onset LBBB and mortality.25,27,32–34,38,54–58
In an analysis from the Placement of AoRtic TraNscathetER Valves
(PARTNER) trial, persistent new-onset LBBB occurred in 10.5% of
cases and was not associated with all-cause mortality, cardiovascular
mortality, stroke, or MI. However, it was associated with a higher rate of
repeat hospitalizations, PPI, and lack of improvement in left ventricular
ejection fraction (LVEF).58 On the other hand, a large multicenter registry
study by Houthuizen et al. reported that TAVR-induced LBBB is one of
the strongest predictors of all-cause mortality in TAVR patients,26 and
can neutralize the benefit of TAVR. A meta-analysis by Regueiro et al.
confirmed a higher risk of cardiac death in patients with TAVR-induced
LBBB after 1 year of follow up.41

following TAVR were independently associated with an increased risk
of SCD.62 Patients with new-onset persistent LBBB and QRS duration
>160 ms had a greater SCD risk and most of them died within 6 months
of TAVR.62 No increased risk of SCD was observed in patients with
new-onset persistent LBBB and pacemaker implanted before hospital
discharge, suggesting HAVB as the main cause of SCD in these
patients.62 The ongoing Ambulatory Electrocardiographic Monitoring for
the Detection of High-Degree Atrio-Ventricular Block in Patients With
New-onset PeRsistent Left Bundle Branch Block After Transcatheter
Aortic Valve Implantation (MARE) study, with continuous EKG recording
(up to 3 years) in patients with new-onset persistent LBBB following TAVR
should provide more information on this issue.

Possible mechanisms of increased mortality for patients with TAVRinduced LBBB are progression to high-grade atrioventricular blocks
(HAVB), and the development of dyssynchrony associated with the
LBBB.26 LBBB causes left ventricular dyssynchrony, which has a similar
effect to chronic right ventricular pacing and can lead to reduction
in left ventricular function and remodeling.59,60 Patients who develop
left ventricular dysfunction from dyssynchrony are also susceptible
to ventricular tachyarrhythmias, which could be another possible
explanation for higher mortality in patients with TAVR-induced LBBB.26 One
case report of a patient without pre-existing conduction abnormalities
who died suddenly in the early phase after discharge, showed autopsy
findings of a THV that had compressed the atrioventricular conduction
system at the septum.61 Microscopic examination confirmed necrosis
of the His bundle and left bundle branch as a result of mechanical
compression, supporting progression to HAVB as a possible mechanism
of sudden cardiac death (SCD).61

Atrioventricular conduction disorders and LBBB occur after both TAVR
and SAVR as a result of the close proximity of the AVN and left bundle
branch to the aortic valve.13 The His bundle is located between the MS
and the posterior crest of the muscular septum; the lower end of MS
is an anatomic landmark for the left ventricular exit point of the His
bundle.13 Consequently, the MS length represents the distance between
the aortic annulus and the His bundle. Hamdan et al. evaluated 73
patients with severe aortic stenosis who underwent contrast-enhanced
CT before TAVR and found that MS length was the most powerful
predictor of HAVB and PPI.63 Short MS, insufficient distance between
MS length and implantation depth, and the presence of calcification in
the basal septum facilitate mechanical compression of the conduction
tissue by the TAVR prosthesis.63 On the other hand, a longer MS length
may allow accommodation of more device penetration without causing
conduction abnormalities.63

Advanced heart failure and SCD account for two-thirds of cardiac deaths
in post-TAVR patients.62 LVEF ≤40% and new-onset persistent LBBB
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Mechanism and Risk Factors of TAVR-induced
LBBB, HAVB, and PPI

LBBB may develop before actual insertion of the valve device in >50% of
cases. This can be caused by contact of the guidewire or compression
of the LVOT by balloon dilatation.29,56 Patient- and procedure-related
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factors such as septal wall thickness, NCC thickness, depth of valve
implantation within the LVOT, post-implantation dilatation, and large size
and type of THV predicts LBBB or new conduction abnormalities after
TAVR.38,54–56,64 Deep THV implants, greater than or equal to 6 mm, are
associated with increased conduction abnormalities and pacemaker
rate.39,65,66 Moreover, higher ratio between prosthesis valve size and the
annulus, (that is, oversizing) in the MCV is considered to be a predictor
of new LBBB.39
Mauri et al. identified risk factors for PPI following TAVR with a balloonexpandable (SAPIEN 3) THV to be a high LVOT calcium volume in the area
below the left coronary cusp and RCC, pre-existing right bundle branch
block (RBBB), and lower implantation depth (Table 2).67 Tarantini et al.
described a relationship between implantation depth and PPI rate after
SAPIEN 3 implantation and proposed an implantation technique aimed at
a maximum LVOT extension of the stent frame of less than 8 mm, which
would result in a ventricular portion of approximately 40.0% depending
on prosthesis size.44 Subsequent studies showed that implantation
techniques aimed at a ventricular portion of <30.0% and <25.5% were
the best discriminatory thresholds for reduced PPI risk.43,67 Optimal
implantation depths for MCV and ESV are between 3 mm and 6 mm and
80% aortic:20% ventricular, respectively.
The radial force from the THV must be sufficient to ensure valve
anchoring, but not interfere with the AVN and disturb the electrical
conduction system.68 Radial force produced by the MCV and ESV was
studied by Tzamtzis et al.69 In self-expanding THVs, the radial force is
dependent on the diameter of LVOT.69 However, the radial force in the
balloon-expandable THVs is associated with a more complex mechanism
that involves the geometric and material properties of the stent, of the
balloon and of the host tissue, as well as the technical aspects of the
balloon inflation procedure.69

Pre-existing Right Bundle Branch Block in Patients
Undergoing Transcatheter Aortic Valve Replacement
Data from the Copenhagen City Heart Study demonstrated that RBBB
was associated with an increased risk for all-cause mortality and
adverse cardiovascular outcomes in the general population.70 A large
meta-analysis of 19 prospective cohort studies confirmed the same
findings; RBBB was associated with an increased risk of mortality in
the general population and in patients with heart disease.71 RBBB is
a well-recognized risk factor for PPI or late bradycardia in post-TAVR
patients.24,72,73 Watanabe et al. evaluated the prognostic effect of
pre-existing RBBB in patients undergoing TAVR in a substudy of the
Optimized Transcatheter Valvular Intervention (OCEAN-TAVI) registry,
which used the SAPIEN XT prosthesis.74 Of 749 patients, 102 (13.6%)
had pre-existing RBBB, and this group had a higher incidence of PPI
than the group without RBBB (17.6% versus 2.9%).74 Patients with
RBBB demonstrated an increased risk of cardiovascular mortality
after TAVR, and were at higher risk of cardiac death if discharged
without pacemakers (HR 2.6).74 A recent study showed a similar result;
RBBB was present on baseline EKG in approximately 10% of patients
and associated with higher 30-day rates of PPI and death.75 Patients
with pre-existing RBBB should be carefully monitored to detect
fatal arrhythmic events after discharge and may require prolonged
hospitalization.
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Table 2: Risk Factors for TAVR-induced LBBB and PPI
Risk Factors for TAVR-induced

Risk Factors for Pacemaker

LBBB

Insertion (PPI)

Patient Characteristics
Baseline QRS duration

Age

–

Male sex

–

Baseline conduction disturbances (i.e.
RBBB)

Anatomical Considerations
Short membranous septum

Short membranous septum

Increased septal wall thickness

Narrow LVOT

Presence of calcification in the
basal septum

High LVOT calcium volume below the
LCC and RCC

Increased non-coronary cusp thickness

Large annular size

–

Mitral annular calcification

Procedural Characteristics
Higher ratio between THV size and
annulus (oversizing)

Higher ratio between THV size and
annulus (oversizing)

Deep THV implantation

Deep THV implantation

Post-dilatation

Intraprocedural atrioventricular block

Type of THV (self- > balloon-expandable)

Type of THV (self- > balloonexpandable)

LBBB = left bundle branch block; LCC = left coronary cusp; LVOT = left ventricular outflow
tract; PPI = permanent pacemaker implantation; RBBB = right bundle branch block; RCC = right
coronary cusp; TAVR = transcatheter aortic valve replacement; THV = transcatheter heart valve.

Predictors and Outcomes of Permanent Pacemaker
Implantation Following TAVR
Positive predictors of PPI post-TAVR are age, male sex, baseline conduction
disturbances, intraprocedural atrioventricular block (AVB), narrow LVOT,
the severity of mitral annular calcification,and use of self-expanding
valve (Table 2).24,76,77 Patients who received PPI were more likely to have
larger THVs implanted, higher oversizing, larger left ventricular internal
diastolic dimensions, larger aortic valve annular size, larger aortic valve
area, and lower aortic valve mean gradient.76 Moreover, septal bulge can
result in a smaller LVOT and increased prosthesis:LVOT diameter ratio,
which increases risk of PPI.73 PPI was associated with longer hospital and
intensive care unit stays,73,76 and significantly increased cost associated
with TAVR.78–80 Most studies reported a median time of 3 days from TAVR
to PPI, and almost 90% of PPIs were performed within 7 days of
TAVR.73,76,81,82 It is believed that conduction abnormalities occurring at a later
time are a result of edema and late expansion of the THV prosthesis.83,84
Chronic right ventricular pacing causes electrical and mechanical
dyssynchrony, and has been associated with a deleterious effect on left
ventricular function and an increased risk of heart failure hospitalizations
in patients with pre-existing heart failure.85–87 Among TAVR patients,
several studies have shown a negative effect of PPI on left ventricular
function at both short- and long-term follow up.30,81,88–90 A retrospective
cohort study of patients undergoing TAVR at 229 sites in the US was
performed using the Society of Thoracic Surgeons/American College of
Cardiology Transcatheter Valve Therapy (STS/ACC TVT) registry and the
Centers for Medicare and Medicaid Services database. The study found
that PPI was required within 30 days of TAVR in 6.7% of cases and varied
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Figure 2: Treatment Algorithms for Management of Conduction Abnormalities Following Transcatheter Aortic
Valve Replacement

A

Baseline EKG

LBBB

Normal QRS

RBBB

TAVR with balloon-expandable valve
Unchanged
QRS

Widened
QRS but <160

Unchanged
QRS

QRS >160

Widened
QRS

Transient
(<24 h)

TVP removal
post-procedure

• Maintain TVP
24 h
• Avoid BB
3–5 days
• Discharge home
with event
monitor

• Maintain TVP
• Avoid BB
3–5 days
• EP study

• TVP removal
after 24 h
• Hold BB
3–5 days

B

Unchanged
RBBB

Complete
heart block

Persist
(>24 h)

• Maintain TVP
• Hold BB
3–5 days
• EP study

• Maintain TVP
48 hours.
• Consider EP study
• Event monitor
or ILR if negative
EP study
• Avoid BB

PPM

Baseline EKG

LBBB

Normal QRS

RBBB

TAVR with self-expanding valve
Unchanged
QRS

Widened
QRS but <120

QRS >120 or
new-onset LBBB

Unchanged
QRS

Widened
QRS
Transient
(<24 h)

• TVP removal
post-procedure
• Continue
telemetry
monitoring

• Maintain TVP
24 h
• Avoid BB
3–5 days
• Discharge home
with event
monitor

• Maintain TVP
• Avoid BB
3–5 days
• EP study

• TVP removal
after 24 h
• Hold BB
3–5 days

Unchanged
RBBB

Complete
heart block

Persist
>24 h

• Maintain TVP
• Hold BB
3–5 days
• EP study

• Maintain TVP
48 h
• Consider EP study
• Event monitor
or ILR if negative
EP study
• Avoid BB

PPM

A: Treatment algorithms for management of conduction abnormalities following TAVR with balloon-expandable valves. B: Treatment algorithms for management of conduction abnormalities
following TAVR with self-expanding valves. BB = beta-blocker; EP = electrophysiology; ILR = implantable loop recorder; LBBB = left bundle branch block; PPM = permanent pacemaker; RBBB = right
bundle branch block; TVP = transvenous pacemaker.

among those receiving self-expanding THVs (25.1%) versus balloonexpanding THVs (4.3%).76 Early PPI is a common complication following
TAVR and was associated with higher mortality and composite endpoint
of mortality or heart failure admission at 1 year.76
Conversely, another recent multicenter study showed PPI was associated
with an increased risk of heart failure rehospitalization and lack of LVEF
improvement, but not total mortality or cardiac mortality, after a median
4-year follow up.90 A meta-analysis by Regueiro et al. also failed to show
any association between PPI and mortality (total and cardiovascular),41
which was similar to the Surgical Replacement and Transcatheter Aortic
Valve Implantation (SURTAVI) trial that did not show any effect of new PPI
post-TAVR on 2-year mortality.4
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A study from the PARTNER trial and registry confirmed PPI after TAVR
had higher rates of repeat hospitalization and a longer duration of
hospitalization, but did not show any association with 1-year mortality.73
Whether more long-term follow-up is needed to better evaluate this risk
of PPI on post-TAVR mortality is yet to be determined, particularly as the
therapy extends to low-risk aortic stenosis patients.

Management of Conduction Abnormalities After
Transcatheter Aortic Valve Replacement
Toggweiler et al. evaluated a cohort of 1,064 patients who underwent
TAVR; 6.7% of patients developed delayed HAVB, of which most cases
occurred within the first 48 hours, and 2.3% had HAVB at 3–8 days
post-TAVR.91 The rates of delayed HAVB in patients with complete RBBB,
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Conduction Abnormalities After Valve Replacement
LBBB, and without bundle branch block (BBB) are 27%, 11%, and 2%,
respectively.91 A first-degree AVB was associated with a higher probability
of subsequent HAVB.91 Overall, the presence of conduction disorders
(BBB, first-degree AVB, or bradycardia in patients with AF) on the EKG
post-TAVR had high sensitivity (99.0%) and negative predictive value
(99.7%) for the occurrence of delayed HAVB.91 The authors propose a
treatment algorithm for the management of conduction abnormalities
post-TAVR (Figure 2).

first 48 hours, patients can be discharged home with an event monitor.
In patients with a self-expandable THV, consider electrophysiology study
with development of a new LBBB. A HV interval >65 ms may be suggestive
of a significant conduction abnormality and warrant PPI; patients with a
HV interval <65 ms can be discharged home with an event monitor. Highrisk patients, such as those with baseline RBBB and bifasicular blocks,
may warrant long-term monitoring with an implantable loop recorder if
early event monitoring is unremarkable.

Without Conduction Disorders

With Post-procedural High-grade Atrioventricular Block

Patients without new BBB and first-degree AVB did not develop
HAVB at 30 days post-TAVR.91 Moreover, the rate of HAVB was low in
patients with AF without BBB or bradycardia.91 The temporary venous
pacemaker (TVP) can be removed immediately post-procedure, and
telemetry monitoring and a daily 12-lead EKG can be continued.
Patients without new BBB and first-degree AVB may be candidates for
early discharge.

PPI is indicated for either third-degree or advanced second-degree AVB at
any anatomic level, which is not expected to resolve, or in the presence
of sinus node dysfunction and documented symptomatic bradycardia.92

With a New Left Bundle Branch Block or First-degree
Atrioventricular Block

TAVR represents a valid option for treatment of severe symptomatic
aortic stenosis. Post-TAVR conduction abnormalities are still a common
complication following both self- and balloon-expandable THVs. Predictors
of TAVR-induced LBBB and PPI depend on baseline patient characteristics
such as preoperative EKG pattern, anatomy of the AVN, His bundle, and
surrounding structures, as well as intra-procedural technical factors.

The risk of HAVB is highest in patients with pre-existing RBBB, followed
by those with LBBB, and first-degree AVB. It is recommended that
TVP is maintained in patients with RBBB and LBBB, and that telemetry
monitoring and a daily 12-lead EKG is continued. Avoid atrioventricular
nodal blocking agents. In patients with a balloon-expandable THV,
consider electrophysiology study if there is a worsening PR interval or the
PR interval is >200 ms, or QRS duration is >160 ms in the first 48 hours.
However, if the PR interval is stable and QRS duration is <160 ms in the

There is no consensus on how to prevent and/or treat post-TAVR
conduction abnormalities. Protocols vary among operators and
valve centers. New generation THVs and modified techniques for
valve implantation may help to reduce the prevalence of PPI. Further
studies are required to validate and establish universal algorithms to
manage conduction abnormalities following TAVR, irrespective of the
prosthesis type.
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